Identifies adults with type 2 diabetes for possible future studies
Identifies adults with type 2 diabetes and reviews their medicine use.
Plain-language title generated from the registry record
Registry title: A Study to Identify and Characterize Patients With Type 2 Diabetes Mellitus for Possible Participation in Ongoing or Future Type 2 Diabetes Mellitus Clinical Studies
Key facts
- Where
- Adana, Ankara, Gaziantep, Istanbul, and Kayseri, TürkiyeSee the 5 sites
Where in Türkiye
- AdanaAdana, TürkiyeNot yet recruiting
- AnkaraAnkara, TürkiyeTaking people
- GaziantepGaziantep, TürkiyeNot yet recruiting
- IstanbulIstanbul, TürkiyeNot yet recruiting
- KayseriKayseri, TürkiyeNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- AstraZeneca
- Trial code
- NCT07606066
- Record updated
- 25 August 2026
- Original description
The purpose of this study is to identify and characterize patients with known Type 2 Diabetes Mellitus (T2DM) for possible participation in ongoing or future T2DM clinical studies, and to characterize trends in key concomitant medication use in this patient population across different geographical regions.Read full original descriptionShow less
A Study to Identify and Characterize Patients With Type 2 Diabetes Mellitus for Possible Participation in Ongoing or Future Type 2 Diabetes Mellitus Clinical Studies
The purpose of this study is to identify and characterize patients with known Type 2 Diabetes Mellitus (T2DM) for possible participation in ongoing or future T2DM clinical studies, and to characterize trends in key concomitant medication use in this patient population across different geographical regions.
Inclusion: Participants must be ≥ 18 years of age at the time of signing the ICF; Patients with a diagnosis of T2DM, test- or documentation-confirmed as per World; Health Organization or local diagnostic standards, inadequately managed with:; Lifestyle management alone, AND/OR; A stable dose of background glucose-lowering medication(s) for T2DM (As specified in the Protocol) for at least 45 days prior to signing the ICF; Expresses interest in participating in an ongoing or future T2DM clinical study, is motivated and willing to make themselves available for the duration of the study, and is able to follow study procedures as required; Provision of signed and dated written informed consent (As specified in the Protocol) before any study-specific procedures, sampling, or analysis.
Exclusion: Diagnosed with Type 1 diabetes mellitus; Current or planned use of GLP-1 RAs prohibited in ongoing or future T2DM studies evaluating the efficacy and safety of investigational GLP-1 RAs (As specified in the Protocol); Known pregnancy at the time of visit or having the intention to become pregnant.